RESUMEN
Fospropofol is a prodrug of propofol which hydrolyzes in the body by alkaline phosphatase to liberate propofol. Propofol liberated from fospropofol has unique pharmacological properties. Fospropofol in doses of 6.5 or 8 mg/kg, is effective and well tolerated for the sedation of patients undergoing colonoscopy,flexible bronchoscopy. When administered intravenously by a dentist anesthesiologist at the indicated dose, it appearsed to be a safe, well-tolerated alternative to midazolam for intravenous moderate sedation during minor oral surgery procedures. In addition, fospropofol provides safe and effective sedation, rapid time to full alert, and high satisfaction in the elderly subset undergoing flexible bronchoscopy, which is comparable with outcomes in younger patients. Study suggested that fospropofol, administered in an infusion/bolus regimen, be tolerable and effective for short-term induction and maintenance of sedation in intensive care unit patients. Fospropofol also could be used to provide general anesthesia in patients undergoing coronary artery bypass graft surgery.